List of Excipients in Branded Drug BRINZOLAMIDE

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Sandoz Inc	BRINZOLAMIDE	brinzolamide	0781-6014	BENZALKONIUM CHLORIDE
Sandoz Inc	BRINZOLAMIDE	brinzolamide	0781-6014	CARBOMER HOMOPOLYMER TYPE C
Sandoz Inc	BRINZOLAMIDE	brinzolamide	0781-6014	EDETATE DISODIUM
Sandoz Inc	BRINZOLAMIDE	brinzolamide	0781-6014	HYDROCHLORIC ACID
Sandoz Inc	BRINZOLAMIDE	brinzolamide	0781-6014	MANNITOL
Sandoz Inc	BRINZOLAMIDE	brinzolamide	0781-6014	SODIUM CHLORIDE

Generic Drugs Containing BRINZOLAMIDE

Company	Ingredient	NDC	Excipient
Padagis US LLC	brinzolamide	0574-4012	BENZALKONIUM CHLORIDE
Padagis US LLC	brinzolamide	0574-4012	CARBOMER HOMOPOLYMER TYPE B
Padagis US LLC	brinzolamide	0574-4012	EDETATE DISODIUM
Padagis US LLC	brinzolamide	0574-4012	HYDROCHLORIC ACID
Padagis US LLC	brinzolamide	0574-4012	MANNITOL
Padagis US LLC	brinzolamide	0574-4012	SODIUM CHLORIDE

What are the Most Frequently-Used Excipients in BRINZOLAMIDE?

# Of NDCs	Excipient
5	BENZALKONIUM CHLORIDE
3	CARBOMER HOMOPOLYMER TYPE B
2	CARBOMER HOMOPOLYMER TYPE C
5	EDETATE DISODIUM
5	HYDROCHLORIC ACID
5	MANNITOL

Brinzolamide Excipient Strategy and Commercial Opportunities

Last updated: October 25, 2026

Brinzolamide is a mature ophthalmic carbonic anhydrase inhibitor marketed primarily as a 1% topical ophthalmic suspension. The commercial opportunity is concentrated in differentiated delivery, preservative-free packaging, improved ocular comfort, combination products, and manufacturing economics rather than in the active ingredient itself. The reference product, Azopt, uses a suspension system built around carbomer 974P, mannitol, sodium chloride, tyloxapol, benzalkonium chloride, disodium edetate, sodium hydroxide, and purified water.[1]

The core brinzolamide molecule has limited remaining lifecycle value as a standalone product. Excipient selection can still support product differentiation if it improves redispersibility, dose uniformity, comfort, microbial control, shelf life, or compatibility with multidose delivery systems.

What is brinzolamide and how is it used?

Brinzolamide is a topical carbonic anhydrase inhibitor used to reduce elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma. Azopt contains brinzolamide at a 1% concentration and is generally dosed as one drop in the affected eye three times daily.[1]

Product characteristic	Reference value
Active ingredient	Brinzolamide
Dosage form	Ophthalmic suspension
Strength	1%
Primary indication	Elevated intraocular pressure
Reference brand	Azopt
Original sponsor	Alcon
Route	Topical ophthalmic
Typical dosing	One drop three times daily
Commercial formulation	Preserved aqueous suspension
Primary preservative	Benzalkonium chloride

Brinzolamide is practically insoluble in water. The suspension format is therefore central to product performance. A formulation must maintain consistent particle distribution, deliver a reproducible dose after shaking, avoid rapid settling or caking, and limit irritation from pH, tonicity, preservatives, and surfactants.

What excipients are used in Azopt brinzolamide ophthalmic suspension?

The Azopt formulation contains the following excipient classes:[1]

Excipient	Functional role in formulation
Carbomer 974P	Suspending polymer and viscosity modifier
Mannitol	Tonicity adjustment and bulking agent
Sodium chloride	Osmolality adjustment
Tyloxapol	Nonionic surfactant and wetting agent
Benzalkonium chloride	Antimicrobial preservative
Disodium edetate	Chelating agent and preservative-support excipient
Sodium hydroxide	pH adjustment
Purified water	Vehicle

The product has a pH of approximately 7.5 and an osmolality close to that of tears.[1] Those parameters are commercially important because brinzolamide suspensions can produce discomfort if the formulation has excessive viscosity, poor wetting, large particles, unsuitable pH, or high osmolality.

Why is carbomer 974P important?

Carbomer 974P provides the suspension structure needed to keep brinzolamide particles distributed throughout the bottle. It also increases viscosity, which can prolong ocular residence time but may create patient complaints if the product feels too thick or leaves transient visual blur.

The main development variables are:

• Polymer concentration.
• Degree of neutralization.
• Mixing order.
• Hydration time.
• Shear exposure.
• Compatibility with surfactants and preservatives.
• Impact on drop size and bottle delivery.
• Effects on particle settling and redispersion.

A formulation using less carbomer or a different rheology modifier may improve comfort and drop delivery, but it must maintain dose uniformity over the full in-use period.

Why are tyloxapol and disodium edetate used?

Tyloxapol improves wetting of brinzolamide particles and assists dispersion in the aqueous vehicle. Poor wetting can cause floating particles, agglomeration, inconsistent dose delivery, and visible sediment.

Disodium edetate binds trace metal ions that can catalyze degradation or reduce preservative performance. It can also support antimicrobial robustness in combination with benzalkonium chloride. Its concentration must be controlled because ophthalmic formulations require a balance between preservative efficacy and ocular tolerability.

What excipient alternatives could differentiate a brinzolamide product?

The strongest formulation opportunities involve preservative reduction, alternative suspension polymers, improved particle engineering, and delivery-device integration.

Preservative-free brinzolamide suspension

Benzalkonium chloride is effective and widely used, but repeated exposure can damage the ocular surface in some patients, particularly those with chronic glaucoma, dry eye, or multiple topical medications. A preservative-free product could target:

• Patients receiving several ophthalmic medicines.
• Patients with ocular-surface disease.
• Long-term glaucoma therapy.
• Postoperative or chronic-care settings.
• Premium branded-generic positioning.

The main technical barrier is multidose microbial control. A preservative-free product generally requires a unidose container, sterile dispensing valve, airless bottle, antimicrobial package, or another validated closure system. The opportunity is therefore a combined formulation-and-device product rather than an excipient substitution alone.

Alternative polymers

Potential alternatives to carbomer include selected cellulose derivatives, polyvinyl alcohol systems, povidone-based systems, poloxamers, and newer ophthalmic mucoadhesive polymers. Each alternative creates different risks:

Polymer approach	Potential advantage	Primary development risk
Hydroxypropyl methylcellulose	Established ophthalmic use and moderate viscosity	May not suspend particles adequately
Hydroxypropyl cellulose	Mucoadhesion and lubricity	Possible impact on clarity and drop size
Polyvinyl alcohol	Familiar ophthalmic excipient	Limited suspension strength at comfortable viscosity
Poloxamer system	Wetting and thermoresponsive behavior	Complex rheology and regulatory justification
Crosslinked polyacrylic acid	Strong suspension capacity	Blur, irritation, and neutralization sensitivity
Mixed-polymer system	Ability to tune suspension and comfort	More complex manufacturing and control strategy

The best commercial candidates are likely to use a lower-viscosity suspension with improved particle size distribution rather than simply increasing polymer concentration.

Particle-size engineering

Brinzolamide particle size affects suspension stability, ocular sensation, dissolution, and dose consistency. Smaller particles can improve uniformity and reduce grittiness, but excessive milling may increase surface energy, agglomeration, or degradation.

Commercially relevant controls include:

• D10, D50, and D90 particle-size distribution.
• Crystal morphology.
• Polymorphic form.
• Surface treatment.
• Milling energy.
• Residual solvent or process impurity profile.
• Sedimentation rate.
• Redispersibility after storage.

Particle engineering can create defensible intellectual property even when the active ingredient patent has expired. Claims may focus on particle-size ranges, morphology, suspension stability, manufacturing conditions, or performance after shaking.

What formulation patents could protect a brinzolamide product?

A new brinzolamide product should use layered protection rather than rely on a single composition claim.

Composition-of-matter and formulation claims

The strongest practical formulation claims may cover:

• Brinzolamide concentration.
• Specific polymer combinations.
• Surfactant-to-drug ratios.
• Preservative-free compositions.
• pH and osmolality windows.
• Particle-size distribution.
• Sedimentation and redispersion performance.
• Reduced ocular irritation.
• Improved dose uniformity.

A narrow claim that links composition to a measurable performance result may be more defensible than a broad claim covering any brinzolamide suspension.

Method-of-use patents

Method-of-use opportunities include:

• Treatment of patients with ocular-surface disease.
• Use in patients intolerant to benzalkonium chloride.
• Reduced-frequency dosing.
• Combination use with prostaglandin analogs or beta blockers.
• Adjunctive treatment in patients inadequately controlled on another glaucoma therapy.
• Administration through a specific preservative-free device.

Method-of-use protection is difficult when the therapeutic indication is already established. The strongest opportunities involve a clinically defined patient population or a demonstrated tolerability benefit.

Manufacturing and process protection

Manufacturing IP can cover:

• Sterile milling.
• Controlled crystallization.
• Particle-size reduction.
• High-shear dispersion.
• Polymer hydration sequence.
• Aseptic filling.
• In-process particle-size controls.
• Container-closure sterilization.

Manufacturing know-how may be more valuable than a broad process patent if the process produces a stable suspension with low batch variability. Trade-secret protection is relevant for mixing order, shear profile, hold times, and scale-up parameters.

What is the FDA regulatory status of brinzolamide?

Brinzolamide is an FDA-approved ophthalmic active ingredient. Azopt was approved in 1998 for reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension.[1]

FDA milestone	Date
Azopt approval	December 1998
Dosage form	Ophthalmic suspension
NDA pathway	505(b)(1) new drug application
Generic pathway	ANDA under section 505(j), where applicable
Reference product	Azopt

A new brinzolamide suspension would typically pursue an abbreviated pathway if it can demonstrate pharmaceutical equivalence and bioequivalence to the reference product. A materially different formulation, delivery system, or clinical benefit could require a more complex regulatory strategy.

For ophthalmic suspensions, regulatory review focuses on:

• Sterility.
• Assay and impurities.
• Particle-size distribution.
• Polymorphic form.
• Redispersibility.
• Delivered dose uniformity.
• Drop size.
• Preservative effectiveness.
• Container-closure integrity.
• Stability after opening.
• Visible and subvisible particulate matter.
• Local tolerability.

What is the Orange Book status of brinzolamide?

The Orange Book identifies FDA-approved reference products, patent information, and regulatory exclusivity relevant to generic entry.[2] Azopt is a mature product, and its core regulatory exclusivity periods have expired. The key commercial issue is therefore the status of listed patents, certifications, and any remaining enforceable claims covering specific formulations, combinations, or uses.

A generic applicant may file with:

• Paragraph I certification if no patent information is listed.
• Paragraph II certification if listed patents have expired.
• Paragraph III certification with a proposed launch after patent expiration.
• Paragraph IV certification alleging that a listed patent is invalid, unenforceable, or not infringed.

For mature ophthalmic products, Paragraph IV risk usually concentrates on formulation, dosing, combination, or device patents rather than the basic active ingredient.

What Paragraph IV challenges could affect brinzolamide?

A Paragraph IV challenge could target claims covering:

• Brinzolamide ophthalmic suspension composition.
• Specific viscosity or pH ranges.
• Preservative systems.
• Combination products containing brinzolamide.
• Container or dispensing systems.
• Method of reducing intraocular pressure.

A Paragraph IV strategy is commercially attractive where the remaining patent claims are narrow and the generic product can avoid them through a different polymer, preservative, particle-size profile, or device. The risk is higher where the reference product has patents tied to a clinically meaningful formulation attribute that is difficult to design around.

When does brinzolamide lose exclusivity?

The original Azopt exclusivity period has already expired. Core brinzolamide generic-entry risk is therefore established rather than prospective. Commercial exclusivity now depends on product-specific patents, regulatory filings, supply contracts, brand loyalty, and formulation differentiation.

Exclusivity layer	Brinzolamide position
Active-ingredient exclusivity	Expired
Original FDA marketing exclusivity	Expired
Core product patent protection	Largely historical
Formulation patents	Must be assessed claim by claim
Combination-product patents	Potentially relevant
Device patents	Potentially relevant
Trade secrets	Relevant to manufacturing economics
Biosimilar protection	Not applicable

Biosimilar competition is not the relevant framework because brinzolamide is a chemically synthesized small molecule. Competition occurs through generic ophthalmic products, authorized generics, branded generics, and differentiated reformulations.

How strong is the patent estate for brinzolamide?

The patent estate for an ordinary 1% brinzolamide suspension is weak relative to a newly launched branded medicine because the active ingredient, indication, and basic dosage form are mature. The estate can become stronger for a differentiated product with measurable technical advantages.

Asset type	Relative strength	Commercial value
Basic brinzolamide composition	Low for new entrants	Limited
Standard 1% suspension	Low to moderate	Supports generic launch
Preservative-free multidose product	Moderate to high	Supports premium positioning
Novel particle engineering	Moderate	May protect quality and performance
Combination product	Moderate	Can delay substitution
Device-integrated delivery	Moderate to high	Creates product-level barriers
Manufacturing process	Moderate	Protects yield and consistency
Clinical tolerability method	Moderate	Depends on evidence quality

Patent strength depends on claim scope, written description, enablement, prosecution history, obviousness exposure, and the availability of non-infringing alternatives. A composition patent covering a narrow excipient ratio may be vulnerable if the formulation is predictable from known ophthalmic suspension technology. A patent supported by comparative data showing improved comfort, redispersion, or dose uniformity is stronger.

What commercial opportunities exist for brinzolamide excipients?

Premium preservative-free products

A preservative-free brinzolamide product could command a premium if it demonstrates better ocular-surface tolerability and offers convenient multidose packaging. The commercial model may support a branded generic, specialty ophthalmology product, or licensing transaction with an ophthalmic manufacturer.

Brinzolamide and timolol combinations

Brinzolamide/timolol fixed-dose combinations reduce administration burden for patients using multiple glaucoma therapies. The opportunity is strongest where the product improves adherence, reduces bottle count, or offers a preservative-free presentation.

Combination products must address compatibility between active ingredients, pH requirements, suspension stability, preservative efficacy, and drop uniformity. They also face substitution and pricing pressure after relevant exclusivity expires.

Contract development and manufacturing

Manufacturers with sterile ophthalmic capability can use brinzolamide as a platform product for:

• Generic suspension development.
• Private-label ophthalmic products.
• Preservative-free filling.
• Dual-chamber or airless packaging.
• Particle-engineered suspensions.
• Combination glaucoma products.

The principal barriers are sterile manufacturing capacity, ophthalmic quality systems, validated filling equipment, and reliable sources of pharmaceutical-grade excipients.

Excipient supplier opportunities

Excipient suppliers can differentiate through:

• Low-bioburden carbomer grades.
• Ophthalmic-grade polymers.
• Preservative-compatible surfactants.
• Low-endotoxin materials.
• Documentation supporting nitrosamine and elemental-impurity controls.
• Custom rheology profiles.
• Supply continuity for sterile or high-purity materials.

For a mature molecule, an excipient supplier with strong regulatory documentation may have greater commercial leverage than a supplier offering an unproven new excipient.

Which companies are likely to challenge or supply brinzolamide?

Competition is likely to come from established generic ophthalmic manufacturers, specialty ophthalmology companies, contract development organizations, and firms with sterile suspension platforms. The relevant competitive advantages are not limited to API access.

Key differentiators include:

• FDA-approved ophthalmic manufacturing capacity.
• Low-cost sterile filling.
• Ability to source carbomer, tyloxapol, and preservative systems.
• Proprietary particle-size control.
• Preservative-free packaging.
• Established ophthalmologist sales channels.
• ANDA portfolio scale.
• Ability to manage patent litigation and Paragraph IV certification.

Large generic companies can compete on price and distribution. Smaller specialty companies may compete through preservative-free delivery, improved tolerability, or fixed-dose combinations.

What generic launch scenarios exist for brinzolamide?

Standard generic launch

A conventional generic would use a formulation close to the reference product, with carbomer-based suspension technology and benzalkonium chloride preservation. This route has the lowest development risk but also the highest price pressure.

Design-around launch

A design-around product could use a different polymer, particle-size distribution, or preservative system. This approach may reduce patent exposure but increases formulation, equivalence, and manufacturing risk.

Premium differentiated launch

A preservative-free, lower-irritation, or device-enabled product could avoid direct price competition. It would require stronger clinical, usability, or tolerability data and may pursue a 505(b)(2) strategy if the formulation or delivery system differs materially from the reference product.

Combination-product launch

Brinzolamide/timolol or another fixed-dose product can reduce administration burden. The product may have greater commercial value than brinzolamide monotherapy but faces more difficult formulation and regulatory requirements.

What patent litigation and settlement issues affect brinzolamide?

Patent litigation risk is product-specific. Generic entrants should evaluate Orange Book-listed patents, Paragraph IV certifications, litigation filed within the statutory period, potential 30-month stays, and any settlement terms affecting launch timing.[2,3]

Settlement agreements may include:

• Delayed generic entry.
• Authorized-generic arrangements.
• Supply or licensing rights.
• Restrictions on formulation or device use.
• Non-cash commercial terms.
• Launch dates linked to litigation outcomes.

Because brinzolamide is a mature product, the largest litigation exposure is likely to arise from a later-generation formulation, fixed-dose combination, or dispensing device rather than from the basic 1% suspension.

Key Takeaways

• Brinzolamide is a mature small-molecule ophthalmic product with expired core exclusivity.
• Azopt uses carbomer 974P, mannitol, sodium chloride, tyloxapol, benzalkonium chloride, disodium edetate, sodium hydroxide, and purified water.
• The most attractive excipient opportunity is a preservative-free or lower-irritation suspension paired with a multidose delivery system.
• Particle-size control, redispersion, viscosity, and dose uniformity are central technical variables.
• New patent value is more likely to come from formulation, device, process, or method-of-use claims than from the active ingredient.
• Biosimilar risk is not applicable; generic and branded-generic competition is the relevant market dynamic.
• A conventional generic has lower development risk but limited pricing power.
• A differentiated product may support licensing or premium positioning if it demonstrates improved tolerability, convenience, or stability.
• Sterile ophthalmic manufacturing and container-closure technology are major barriers to entry.
• Orange Book and Paragraph IV analysis must be performed at the product and patent-claim level.

FAQs

Is brinzolamide soluble in water?

No. Brinzolamide has limited water solubility, which is why Azopt is formulated as an ophthalmic suspension rather than a simple aqueous solution.

Can benzalkonium chloride be removed from brinzolamide ophthalmic products?

Yes, but removal requires a different microbial-control strategy, such as unit-dose packaging, a validated preservative-free multidose container, or another sterile dispensing system.

What is the best excipient for suspending brinzolamide?

Carbomer 974P is the established reference-product approach. Alternative polymers may improve comfort or manufacturability, but they must preserve dose uniformity, redispersibility, sterility, and ocular tolerability.

Is a brinzolamide/timolol combination more commercially attractive than brinzolamide alone?

Potentially. A fixed-dose combination can reduce bottle burden and improve convenience, but it faces more demanding compatibility, stability, regulatory, and patent requirements.

Can a new brinzolamide suspension receive new patent protection?

Yes. New protection may be available for a novel excipient combination, particle-size profile, preservative-free system, delivery device, manufacturing process, or clinically supported method of use. The claims must provide a meaningful technical distinction over known brinzolamide suspensions.

References

1. Alcon Laboratories, Inc. (2017). Azopt (brinzolamide ophthalmic suspension) 1% prescribing information. U.S. Food and Drug Administration.

2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.

3. U.S. Food and Drug Administration. (2024). Abbreviated new drug application approvals and patent certification requirements. FDA.

4. U.S. Pharmacopeia. (2024). General chapter <771>: Ophthalmic products. United States Pharmacopeial Convention.

5. U.S. Food and Drug Administration. (1998). Azopt approval package and clinical pharmacology review. FDA.